MEF2C Network Drives Glomerular Endothelial Proliferation in Diabetic Kidney Disease

Diabetic kidney disease remains the primary driver of end-stage renal disease in the developed world, accounting for nearly 50% of all cases [1]. While optimizing glycemic control is a standard clinical priority, high HbA1c variability (fluctuations in long-term blood glucose levels) is associated with a 1.34-fold increased risk of renal disease (95% CI, 1.15 to 1.57) in patients with type 2 diabetes [2]. Because these microvascular complications often progress despite strict blood pressure management, researchers are increasingly focusing on the glomerular niche (the specialized microenvironment where blood filtration occurs) to identify new therapeutic targets [1, 3]. A recent multiomics analysis of 132 human kidney samples has identified a specific gene regulatory network (a collection of molecular regulators that interact to control cell function) involving the transcription factors MEF2C, MEF2A, and TRPS1 [4]. This network governs the transition of healthy glomerular capillary endothelial cells into a proliferative injured phenotype, a state characterized by abnormal cell growth and neovascularization that may be modulated by sodium glucose transporter-2 inhibitor therapy [4, 5].